S&P 5007,175.83▼2.0% Nasdaq23,879.20▼2.2% Dow49,097.06▼2.2% Russell 2K2,655.11▼2.2% 10-Yr5.05%−1bp VIX28.44+3.88 WTI$83.08▼0.2% Gold$3,634.50▼2.9% EUR/USD1.097▼0.2% BTC$61,902▼1.7% Nikkei59,024▲0.3%
At close · Thu, Nov 19, 2026
Daily Market Updates.

Earnings

Home›Earnings›Results›Revolution Medicines reports updated pancreatic cancer…

Revolution Medicines reports updated pancreatic cancer trial results

61 patients in first-line metastatic PDAC cohort received 200 mg of Rasonque plus GnP

Revolution Medicines, Inc. announced updated findings from its Phase 1/2 RMC-GI-102 study of Rasonque combined with gemcitabine and nab-paclitaxel for metastatic pancreatic adenocarcinoma. The analysis revealed a confirmed objective response rate of 60.7% and a 90.2% disease control rate. As of September 28, 2026, 61 patients received 200 mg of Rasonque plus GnP, achieving a median follow-up of 18.3 months.

The regimen delivered a median duration of response of 11.1 months and a median progression-free survival of 12.8 months. Patients also experienced a 12-month overall survival rate of 76.6%. The combination therapy maintained a safety profile consistent with prior observations for both components.

More like this

Sources

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.